Notably, the therapeutic potential of targeting FAM110B has been demonstrated not only in pancreatic and colon cancers, but also in several other cancer types, including non-small cell lung cancer and prostate cancer (Xi and Zhang, 2018; Wang et al., 2020a). This evidence concerns the gene FAM110B and cancer.